In order to investigate the effects of K-351 (Nipradilol), a single-blind controlledstudy was performed in 10 patients with chronic stable angina pectoris .
A multistage treadmill test was performed by the Bruce protocol on the control (drugfree) and at 2 hours after a single oral administration of either placebo or the activedrug (K-351, 6mg). Blood samples were taken for the measurement of plasmaconcentrations of K-351 just before the treadmill test.
Analysis of variance showed that K-351 significantly improved exercise duration by27% and the time to the onset of ischemia by 46%, as compared with placebo. K-351also significantly decreased peak heart rate, peak rate-pressure products, and systolicblood pressure at the, same level of exercise as the peak exercise level with placebo .
Plasma levels of K-351 ranged from 1.4 to 7.8ng/ml with the mean of 5.3±1.8ng/ml. There was no relation between plasma levels and exercise capacity .
In conclusion K-351 significantly increased exercise tolerance in patients withchronic stable angina pectoris.
